The effect of time to antifungal therapy on mortality in candidemia associated septic shock

American Journal of Therapeutics

Volumn 16, Issue 6, 2009, Pages 508-511

  Patel, Gourang P ^a   Simon, David ^a   Scheetz, Marc ^b   Crank, Christopher W ^b   Lodise, Thomas ^c   Patel, Nimish ^c  

^a RUSH UNIVERSITY   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Candida; Candidemia; Septic shock; Time to antifungal therapy

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; HYPERTENSIVE AGENT; VORICONAZOLE;

ADULT; AGED; ARTICLE; BLOOD CULTURE; CANDIDA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; CANDIDEMIA; CLAVISPORA LUSITANIAE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTENSIVE CARE; LOG RANK TEST; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCORING SYSTEM; SEPTIC SHOCK; TIME; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ANTIFUNGAL AGENTS; CANDIDIASIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITAL MORTALITY; HUMANS; INPATIENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SHOCK, SEPTIC; SURVIVAL RATE; TIME FACTORS;

EID: 74549138201     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181a1afb7     Document Type: Article

References (12)

1. Wisplinghoff H, Jones RN, Messer SA, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a nationwide surveillance study. Clin Infect Dis. 2004;39:309-317.
2. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146-155.
3. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005; 49:3640-3645.
4. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28:1071-1079.
5. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest. 1992;101:1644-1655.
6. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
7. Harrell FE Jr, Lee KL, Matchar DB, et al. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep. 1985;69:1071-1077.
8. Hadley S, Lee WW, Ruthazer R, et al. Candidemia as a cause of septic shock and multiple organ failure in non immunocompromised patients. Crit Care Med. 2002;30: 1808-1814.
9. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31.
10. Pappas PG, Rex JH, Sobel, JD, et al. Guidelines for the treatment of candidiasis. Clin Infect Dis. 2004;38:161-189.
11. Labelle AJ, Micek ST, Roubinian N, et al. Treatmentrelated risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008;36:2967-2972.
12. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589-1596.